Lanean...
Immunotherapy for head and neck cancer: Recent advances and future directions
Three randomized phase III trials have now conclusively proven that exposure to a PD-1 inhibitor prolongs survival in recurrent/metastatic (R/M) HNSCC, and it is clear that such agents should be used in the management of all patients who do not have contraindications to their use. Two of these phase...
Gorde:
| Argitaratua izan da: | Oral Oncol |
|---|---|
| Egile Nagusiak: | , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
2019
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7749717/ https://ncbi.nlm.nih.gov/pubmed/31683169 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.oraloncology.2019.104460 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|